512 related articles for article (PubMed ID: 31570282)
1. BRCA1/2 somatic mutation detection in formalin-fixed paraffin embedded tissue by next-generation sequencing in Korean ovarian cancer patients.
Lee A; Kang J; Lee H; Lee YS; Choi YJ; Lee KH; Nistala GJ; Scafe CR; Choi J; Yoo J; Han M D E; Kim Y; Kim M
Pathol Res Pract; 2019 Nov; 215(11):152595. PubMed ID: 31570282
[TBL] [Abstract][Full Text] [Related]
2. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
Mafficini A; Simbolo M; Parisi A; Rusev B; Luchini C; Cataldo I; Piazzola E; Sperandio N; Turri G; Franchi M; Tortora G; Bovo C; Lawlor RT; Scarpa A
Oncotarget; 2016 Jan; 7(2):1076-83. PubMed ID: 26745875
[TBL] [Abstract][Full Text] [Related]
3. Validation of multi-gene panel next-generation sequencing for the detection of BRCA mutation in formalin-fixed, paraffin-embedded epithelial ovarian cancer tissues.
Kim ET; Jeong HE; Yoon HJ; Kim KH; Suh DS
Taiwan J Obstet Gynecol; 2023 Jan; 62(1):66-70. PubMed ID: 36720553
[TBL] [Abstract][Full Text] [Related]
4. Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples.
Zakrzewski F; Gieldon L; Rump A; Seifert M; Grützmann K; Krüger A; Loos S; Zeugner S; Hackmann K; Porrmann J; Wagner J; Kast K; Wimberger P; Baretton G; Schröck E; Aust D; Klink B
BMC Cancer; 2019 Apr; 19(1):396. PubMed ID: 31029168
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer.
Chao A; Chang TC; Lapke N; Jung SM; Chi P; Chen CH; Yang LY; Lin CT; Huang HJ; Chou HH; Liou JD; Chen SJ; Wang TH; Lai CH
Oncotarget; 2016 Dec; 7(51):85529-85541. PubMed ID: 27907908
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous detection of BRCA mutations and large genomic rearrangements in germline DNA and FFPE tumor samples.
Enyedi MZ; Jaksa G; Pintér L; Sükösd F; Gyuris Z; Hajdu A; Határvölgyi E; Priskin K; Haracska L
Oncotarget; 2016 Sep; 7(38):61845-61859. PubMed ID: 27533253
[TBL] [Abstract][Full Text] [Related]
7. Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples.
Badoer C; Garrec C; Goossens D; Ellison G; Mills J; Dzial M; El Housni H; Berwouts S; Concolino P; Guibert-Le Guevellou V; Delnatte C; Del Favero J; Capoluongo E; Bézieau S
Oncotarget; 2016 Dec; 7(49):81357-81366. PubMed ID: 27793035
[TBL] [Abstract][Full Text] [Related]
8. Detection of somatic BRCA1/2 mutations in ovarian cancer - next-generation sequencing analysis of 100 cases.
Koczkowska M; Zuk M; Gorczynski A; Ratajska M; Lewandowska M; Biernat W; Limon J; Wasag B
Cancer Med; 2016 Jul; 5(7):1640-6. PubMed ID: 27167707
[TBL] [Abstract][Full Text] [Related]
9. Somatic mutations in BRCA1&2 in 201 unselected ovarian carcinoma samples - single institution study.
Kowalik A; Zalewski K; Kopczyński J; Siołek M; Lech M; Hińcza K; Kalisz J; Chrapek M; Zięba S; Furmańczyk J; Jedliński M; Chłopek M; Misiek M; Góźdź S
Pol J Pathol; 2019; 70(2):115-126. PubMed ID: 31556562
[TBL] [Abstract][Full Text] [Related]
10. An optimized
Kim Y; Cho CH; Ha JS; Kim DH; Kwon SY; Oh SC; Lee KA
J Gynecol Oncol; 2020 Jan; 31(1):e9. PubMed ID: 31788999
[TBL] [Abstract][Full Text] [Related]
11. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
[TBL] [Abstract][Full Text] [Related]
12. Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis.
Fumagalli C; Rappa A; Casadio C; Betella I; Colombo N; Barberis M; Guerini-Rocco E
J Clin Pathol; 2020 Mar; 73(3):168-171. PubMed ID: 31537627
[TBL] [Abstract][Full Text] [Related]
13. Recurrent BRCA1 Mutation, but no BRCA2 Mutation, in Vietnamese Patients with Ovarian Carcinoma Detected with Next Generation Sequencing.
Vu HA; Phu ND; Khuong LT; Hoa PH; Nhu BTH; Nhan VT; Thanh LQ; Sinh ND; Chi HT; Quan ND; Binh NT
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2331-2335. PubMed ID: 32856862
[TBL] [Abstract][Full Text] [Related]
14. Implementing NGS-based
Rivera D; Paudice M; Gismondi V; Anselmi G; Vellone VG; Varesco L;
J Clin Pathol; 2021 Sep; 74(9):596-603. PubMed ID: 32895300
[TBL] [Abstract][Full Text] [Related]
15. NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial.
Endris V; Stenzinger A; Pfarr N; Penzel R; Möbs M; Lenze D; Darb-Esfahani S; Hummel M; Sabine-Merkelbach-Bruse ; Jung A; Lehmann U; Kreipe H; Kirchner T; Büttner R; Jochum W; Höfler G; Dietel M; Weichert W; Schirmacher P
Virchows Arch; 2016 Jun; 468(6):697-705. PubMed ID: 27003155
[TBL] [Abstract][Full Text] [Related]
16. [Testing of mutations in BRCA1 and BRCA2 genes in tumor tissues - possibilities and limitations].
Vošmiková H; Ryška A; Sieglová K; Laco J
Cesk Patol; 2016; 52(4):210-214. PubMed ID: 27869447
[TBL] [Abstract][Full Text] [Related]
17. Validation of BRCA testing on cytologic samples of high-grade serous carcinoma.
Lou SK; Grenier S; Care M; McCuaig J; Stockley TL; Clarke B; Ruff HM; Boerner SL
Cancer Cytopathol; 2021 Nov; 129(11):907-913. PubMed ID: 34157791
[TBL] [Abstract][Full Text] [Related]
18. BRCA1/2 NGS Somatic Testing in Clinical Practice: A Short Report.
Pepe F; Pisapia P; Russo G; Nacchio M; Pallante P; Vigliar E; De Angelis C; Insabato L; Bellevicine C; De Placido S; Troncone G; Malapelle U
Genes (Basel); 2021 Nov; 12(12):. PubMed ID: 34946865
[TBL] [Abstract][Full Text] [Related]
19. Detection of BRCA1/2 large genomic rearrangement including BRCA1 promoter-region deletions using next-generation sequencing.
Han E; Yoo J; Chae H; Lee S; Kim DH; Kim KJ; Kim Y; Kim M
Clin Chim Acta; 2020 Jun; 505():49-54. PubMed ID: 32092317
[TBL] [Abstract][Full Text] [Related]
20. Peritoneal washing is an adequate source for somatic BRCA1/2 mutation testing in ovarian malignancies.
Barquín M; Maximiano C; Pérez-Barrios C; Sanchez-Herrero E; Soriano M; Colmena M; García-Espantaleón M; Tejerina González E; Gutierrez L; Sánchez Ruiz AC; Torrente M; Provencio M; Romero A
Pathol Res Pract; 2019 Feb; 215(2):392-394. PubMed ID: 30392916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
